HOME >> BIOLOGY >> NEWS
Study of flu patients reveals virus outsmarting key drug

MADISON - A drug envisioned as a front-line defense for the next flu pandemic might have a genetic Achilles' heel that results in a drug-resistant influenza virus capable of infecting new human hosts, according to a study published this week (Aug. 28) in the British medical journal The Lancet.

The study of Japanese children with influenza and treated with the antiviral drug oseltamivir was conducted by an international team of researchers led by virologist Yoshihiro Kawaoka of the University of Wisconsin-Madison and the University of Tokyo. Results of the study showed that nearly 20 percent of patients treated with the drug produced mutant drug-resistant viruses as soon as four days after treatment. Moreover, patients continued to shed significant amounts of infectious viral particles even after five days of treatment with the potent antiviral agent.

"The problem with this compound is that a single (genetic) mutation makes the virus resistant," says Kawaoka, an authority on influenza who holds an appointment at the UW-Madison School of Veterinary Medicine.

The finding is important because it provides evidence that influenza viruses can easily and quickly thwart one of the few lines of defense for a disease that claims many lives each year and that, in a pandemic, is among the world's most feared and deadly diseases.

"The importance of this work is that when a pandemic occurs with a new virus and this drug is extensively used, then we may be faced with the rapid appearance of resistant viruses," Kawaoka says.

At present, there are only two strategies for stemming the spread of influenza: vaccines and antiviral drugs. Vaccines use inactivated forms of a virus to ramp up the immune system and thwart infection. Antiviral drugs such as oseltamivir work by inhibiting key proteins on the surface of the virus, effectively locking them in their host cells and preventing the virus from escaping and infecting new cells and hosts.


'"/>

Contact: Yoshihiro Kawaoka
kawaokay@svm.vetmed.wisc.edu
University of Wisconsin-Madison
26-Aug-2004


Page: 1 2 3

Related biology news :

1. Study: Emission of smog ingredients from trees is increasing rapidly
2. Study explores gene transfer to modify underlying course of Alzheimers disease
3. Study reveals why eyes in some paintings seem to follow viewers
4. Study by Israeli scientists provides insight on DNA code
5. Study reveals first genetic step necessary for prostate cancer growth
6. Study in Science reveals recreational fishing takes big bite of ocean catch
7. Study suggests cell-cycle triggers might be cancer drug targets
8. Study narrows search for genes placing men at increased risk for prostate cancer
9. Study links high carbohydrate diet to increased breast cancer risk
10. Study explains spatial orientation differences between sexes
11. Study suggests humans can speed evolution

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/23/2020)... (PRWEB) , ... June 22, 2020 , ... The field ... Typically, ligand binding assays (LBA) have dominated this area. However, the use of mass ... years. , This now necessitates the question “How do you choose which approach to ...
(Date:6/19/2020)... ... ... Join experts from Envigo Lauren Klaskala, Project Manager – Custom Transgenic Models ... July 8, 2020 at 11am EDT (4pm BST/UK). , Nuclease-based technologies such as CRISPR ... the genome may be more straightforward, the challenge to create an optimal model for ...
(Date:6/5/2020)... ... June 04, 2020 , ... “Although we are disappointed ... well-being of our attendees, staff, and the public. We remain committed to creating ... ways to collaborate virtually,” said Julie Sutcliffe, President of WMIS. , ...
Breaking Biology News(10 mins):
(Date:5/15/2020)... (PRWEB) , ... May 14, 2020 , ... ... to undergo multiple open heart surgeries before becoming adults. The reason: ... , To address this critical unmet need, the Department of Defense has awarded ...
(Date:5/15/2020)... ... , ... Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to ... Ganz will continue to lead Sentien’s Board of Directors, a role he has filled ... and Sentien’s management team. , Mr. Ganz has more than 30 years ...
(Date:5/14/2020)... ... May 12, 2020 , ... NanoString Technologies ... together thousands of industry leaders, clinicians, research scientists, medical professionals and academics from ... June, MD, Director of the Center for Cellular Immunotherapies at the Perelman School ...
(Date:5/14/2020)... ... May 13, 2020 , ... Early ... readouts, providing little or no information on the drug’s mechanism of action (MOA). ... of compounds by measuring the activity of molecular pathways. This information can complement ...
Breaking Biology Technology:
Cached News: